NCT02180061View on ClinicalTrials.gov

Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 15, 2014

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Melanoma
Interventions
BIOLOGICAL

Pembrolizumab

IV infusion

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02180061 - Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041) | Biotech Hunter | Biotech Hunter